This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third opinion: Discussing the standard of care for chronic gout and potential of SEL-212 from Selecta Biosciences
Ticker(s): SELB, HZNWho's the expert?
Institution: Singing River Health System
- Board certified Rheumatologist in clinical practice for 18 years.
- Manages 1200 RA patients, 450 PsA patients, and 45-50 scleroderma patients in a non-academic community hospital system.
- Prescribes tofacitinib for RA, PsA, and UC.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
